President Donald Trump’s administration has released a breakdown of its attempts to cut back on healthcare and research spending across the government, with…

Shares in Puma Biotechnology jumped 40% after the FDA trod lightly around doubts about its filing for approval of breast cancer drug neratinib.

Perennial biotech investor and backer Takeda has signed its latest collaboration with Nektar Therapeutics that will see the pair work on combo cancer…

Amgen and UCB's romosozumab trounced a comparator drug in a trial in osteoporosis, but there's a big catch: The therapy seems to cause side effects…

Shire and drug partner Xenetic have released new data for their collaborative bleeding disorder drug SHP656, and the news isn’t good.

Ablynx and Merck KGaA have moved their osteoarthritis candidate to the cusp of the clinic.

La Jolla Pharmaceutical has posted a full look at data from a phase 3 trial of its vasodilatory shock candidate LJPC-501.

Argenx’s IPO fundraising total has come to a stop at $144.7 million, more than 50% above its initial target.

The EU's drug review committee has followed through on an earlier warning and rejected XBiotech's metastatic colorectal cancer candidate Xilonix.